Introgen reports biomarker link to new therapy

Introgen Therapeutics says that their researchers have found a statistically significant link between an abnormal p53 biomarker and response to their experimental therapy for head and neck cancer. The researchers plan to use that knowledge in analyzing data from a late-stage trial of Advexin. The company had already amended its INDA to include an analysis of the response to the drug by patients with the abnormal p53 biomarker. According to Introgen: "Tumor response after Advexin monotherapy was observed in 35 percent of patients with the abnormal p53 biomarker and all tumor responses occurred in the abnormal p53 biomarker group. The majority of these patients had recurrent disease after receiving standard therapies."

- see the release on the data

Related Articles:
Introgen touts cancer data. Report
Reactivated p53 gene plays role in fighting tumors. Report

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.